Allison M. Bock
( out of 87 reviews )

Allison M. Bock, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her Internal Medicine residency training at the University of Colorado and fellowship training in Hematology/Oncology at the Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute, including an investigator-initiated randomized phase 2 study evaluating a bispecific antibody therapy for patients at high risk of relapse post CAR-T. She is also an active participant within the national Southwest Oncology Group. She has medical licensure in the states of UT, WY, MT, and ID in order to provide better access to care for the rural communities HCI serves.

    To schedule an appointment New Patients: 801-585-6906 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 87 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    May 23, 2025
    HUNTSMAN CANCER CENTER

    Dr. Bock is an exceptional physician who is intelligent, caring, and wise in her recommendations. She listens carefully, and displays compassion. She explains things well and confidently moves in the direction that is best for you as a patient. She is quick in ordering tests to bring about the answers needed for an accurate diagnosis. Most importantly, she has an a way of instilling peace and calm during the unknown. IÕm so grateful I am under her care.

    May 21, 2025
    HUNTSMAN CANCER CENTER

    She was very professional, knowledgable about my particular case, and friendly. I feel a lot of trust in her and her staff.

    May 12, 2025
    HUNTSMAN CANCER CENTER

    Great Doctor very knowledgeable.

    May 02, 2025
    HUNTSMAN CANCER CENTER

    Dr Bock and her entire team including the supporting lab are absolutely the best imaginal both professionally and in personal connection

    April 26, 2025
    HUNTSMAN CANCER CENTER

    Dr. Bock is the kind of doctor you hope to get when your life is being threatened by disease. She's so knowledgeable in her field. You feel confident that she knows the right paths to take and makes sure you understand those paths. Her staff is exceptional and gives you the same level of care in her absence. She has taken me from a diagnosis of 5 days to live to 4 months later and only a couple more treatments to go and feeling happy and hopeful with a full future.

    April 22, 2025
    HUNTSMAN CANCER CENTER

    Incredible knowledgeable and very nice. So glad she's my doctor.

    April 08, 2025
    HUNTSMAN CANCER CENTER

    Listens well to my concerns and provides reasonable solutions and accommodations to support me.

    April 01, 2025
    HUNTSMAN CANCER CENTER

    She's amazing!! Thoughtful and knows her stuff!

    March 26, 2025
    HUNTSMAN CANCER CENTER

    She is excellent doctor

    See More Patient Comments

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her Internal Medicine residency training at the University of Colorado and fellowship training in Hematology/Oncology at the Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute, including an investigator-initiated randomized phase 2 study evaluating a bispecific antibody therapy for patients at high risk of relapse post CAR-T. She is also an active participant within the national Southwest Oncology Group. She has medical licensure in the states of UT, WY, MT, and ID in order to provide better access to care for the rural communities HCI serves.

    To schedule an appointment New Patients: 801-585-6906 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - Mayo Clinic Fellow
    Residency Internal Medicine - University of Colorado School of Medicine Resident
    Professional Medical Medicine; Global Health Pathway - Medical College of Wisconsin M.D.
    Undergraduate Genetics, Cell Biology and Development; minor in Psychology - University of Minnesota - Twin Cities B.S.

    Selected Publications

    Journal Article

    1. Novak A, Walker J, Wenzl K, Novak J, Stokes M, Hopper M, Dropik A, Siminski M, Bock AM, Sarangi V, Ortiz M, Stong N, Huang C, Maurer M, Link B, Ansell S, Habermann T, Witzig T, King R, Nowakowski G, Cerhan J, and Gandhi A (). Integrated genomics with refined cell-of-originsubtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuselarge B cell lymphoma. (Epub ahead of print) Blood Cancer J.
    2. Walker JS, Wenzl K, Novak JP, Stokes ME, Hopper MA, Dropik AR, Siminski MS, Bock AM, Sarangi V, Ortiz M, Stong N, Huang CC, Maurer MJ, Link BK, Ansell SM, Habermann TM, Witzig TE, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ (2025). Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma. Blood Cancer J, 15(1), 120. (Read full article)
    3. Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks TW, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS (2025). Defining Primary Refractory Large B-cell Lymphoma. Blood Adv.
    4. Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah HR (2025). Comparison of Real-World Outcomes in Patients with Follicular Lymphoma treated with BR vs RCHOP-like regimens. Clin Lymphoma Myeloma Leuk.
    5. Pierce AL, Okcu I, Nowakowski G, Tolu S, Amengual J, Ross C, Graber J, Bock A, Hu B, Ermann D (2025). HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era. J Natl Compr Canc Netw, 23(3.5). (Read full article)
    6. Bock AM, Wenzl K, Novak JP, Stokes ME, Hopper MA, Krull JE, Dropik AR, Sarangi V, Ortiz M, Stong N, Huang CC, Maurer MJ, King RL, Farooq U, Wang Y, Witzig TE, Ansell SM, Habermann TM, Cerhan JR, Gandhi AK, Nowakowski G, Novak AJ (2024). Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance. Hematol Oncol, 43(1), e70006. (Read full article)
    7. Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton MR, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein PG, Chaudhry A, Olszewski AJ (2024). High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. Blood Adv, 8(20), 5355-5364. (Read full article)
    8. Okcu I, Wang Y, Bock AM, Zhou J, Moustafa MA, Tun HW, Rosenthal AC, Johnston PB, Baidoun F, Khurana A, Kabat BF, King RL, Habermann TM, Nowakowski GS (2024). Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clin Lymphoma Myeloma Leuk.
    9. Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Witzig TE, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ (2024). Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood Cancer J, 14(1), 100. (Read full article)
    10. Hines AS, Koster MJ, Bock AR, Go RS, Warrington KJ, Olteanu H, Lasho TL, Patnaik MM, Reichard KK (2022). Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome. Rheumatology (Oxford), 62(12), 3947-3951. (Read full article)
    11. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv, 7(21), 6381-6394. (Read full article)
    12. Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang Y (2023). Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J, 13(1), 169. (Read full article)
    13. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Tognon C, Bock AM, Pollyea DA, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal A (2021). Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood, 139(8), 1208-1221. (Read full article)
    14. Simpson HM, Bock A, Cervantes L (2021). Policy in clinical practice: Emergency Medicaid and access to allogeneic stem cell transplant for undocumented immigrants. J Hosp Med, 17(1), 50-53. (Read full article)
    15. Canfield GS, Bock A, Mann S, Zimmer S, Somerset H, Franco-Paredes C, Wilson CC, Metter RB (2020). A 31-year-old Micronesian Man With Shoulder Fungating Mass. Clin Infect Dis, 70(5), 973-975. (Read full article)
    16. Bock AM, Brunmeier A, Wichman CL, Bergl PA (2017). Encephalopathy With Psychosis Following Group A Streptococcal Sepsis-An Immune-Mediated Phenomenon? Psychosomatics, 58(5), 551-555. (Read full article)
    17. Bock AM, LeVeque M, Camitta B, Talano JA (2016). Successful treatment of recurrent CNS disease post-bone marrow transplant in children with familial hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 63(12), 2154-2158. (Read full article)
    18. Bock A, Chintamaneni K, Rein L, Frazer T, Kayastha G, MacKinney T (2016). Improving pneumococcal vaccination rates of medical inpatients in urban Nepal using quality improvement measures. BMJ Qual Improv Rep, 5(1). (Read full article)
    19. Knorr DA, Bock A, Brentjens RJ, Kaufman DS (2013). Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem Cells Dev, 22(13), 1861-9. (Read full article)
    20. Bock AM, Knorr D, Kaufman DS (2013). Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs). J Vis Exp, (74), e50337. (Read full article)
    21. Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf DJ (2012). Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant, 19(1), 102-8. (Read full article)

    Review

    1. Bock AM and Epperla N (In press). Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. [Review]. J Hematol Oncol.
    2. Bock AM, Epperla N (2025). Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. [Review]. J Hematol Oncol, 18(1), 68. (Read full article)
    3. Bock AM, Nowakowski GS, Wang Y (2022). Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. [Review]. Curr Treat Options Oncol, 23(2), 155-170. (Read full article)

    Letter

    1. Ng WL, Wang Y, Bock AM, Jevremovic D, Wang ML, Nowakowski GS (2023). Review of management options for mantle cell lymphoma in pregnancy. [Letter to the editor]. Leuk Lymphoma, 64(6), 1194-1198. (Read full article)
    2. Bock AM, Pollyea DA (2020). Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemia. [Letter to the editor]. Am J Hematol. (Read full article)

    Abstract

    1. Bock AM, Baron K, Wagner C, Fitzgerald L, Ermann D, Hu B, Shah H, Zak J, Epperla N (2025). Impact Of the Neutrophil/Lymphocyte Ratio on Outcomes Following Bispecific Antibody Therapy in Relapsed/Refractory Lymphoma Patients [Abstract].
    2. Jallouk A, Feng L, Ayers A, Chauhan A, Thiruvengadam S, Bock A, Bhaskar S, Epperla N, Herrera A, Ahmed S (2025). Real-World Outcomes of Mosunetuzumab Use from the Cubic Consortium [Abstract].
    3. Baron K, Wagner C, Fitzgerald LA, Ermann DA, Hu B, Epperla N, Shah HA, Bock A (2025). A Standardized Process for a Rapid Dose Escalation of Epcoritamab for Patients with Lymphoid Malignancies in the United States [Abstract].
    4. Bock AM, Feng L, Ayers A, Chauhan A, Thiruvengadam S, Jallouk A, DAngelo C, Sawalha Y, Godbole S, Merryman R, Bhaskar S, Baron K, Lunning M, Herrera A, Crombie JL, Epperla N, Ahmed S (2025). Real-World Safety and Efficacy of Epcoritamab for Patients with Relapsed/Refractory Large B-Cell Lymphomas [Abstract].
    5. Shouse G, Ahmed S, Chen L, Salles G, Bock AM, Lunning MA, Godbole S, Sawalha Y, Ayers AA, Thiruvengadam S, Goth C, Flowers CR, Chauhan A, Epperla N, Herrera A, Danilov AV, Falchi L (2025). Glofitamab for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma, a Real-World Evidence Study from the Cubic Consortium [Abstract].
    6. Steiner R, Bock AM, Herrera AF, Zulfa O, Hoffmann M, Ibrahimi S, Galanina N, Lee HJ, Green M, Lin R, Pinnix CC, Moskowitz A, Yahalom J, Chihara D (2025). CTEP Trial 10590, Norm: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial With Either Rituximab or Mosunetuzumab [Abstract].

    Other

    1. Stromich J, Saleh J, Jha P, Bangalore-Raju S, Bock A, Singh M, Lamb G, Tyagi S, Pfeifer K, Katz A, Wagle J, Dang G, Koerner K, Lalehzari M (July 2017). Cases from the Medical College of Wisconsin. Ocular syphilis, cefepime neurotoxicity, primary empty sella, and more. ACP Hospitalist. American College of Physicians.